Humacyte (HUMA) Shares Outstanding (Weighted Average) (2020 - 2026)

Humacyte (HUMA) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $197.8 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $197.8 million, up 50.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $197.8 million (up 50.46% YoY), and the FY2025 annual result was $158.2 million, up 1023.35% from the prior year.
• Shares Outstanding (Weighted Average) improved to $197.8 million in Q1 2026 per HUMA's latest filing, from $40.9 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $197.8 million in Q1 2026 and troughed at $5.6 million in Q1 2023.
• A 5-year average of $96.9 million and a median of $103.4 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) surged 24972.96% in 2022, then tumbled 94.6% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $103.1 million in 2022, then rose by 0.36% to $103.4 million in 2023, then plunged by 86.39% to $14.1 million in 2024, then surged by 190.75% to $40.9 million in 2025, then soared by 383.31% to $197.8 million in 2026.
• Business Quant data shows HUMA's Shares Outstanding (Weighted Average) at $197.8 million in Q1 2026, $40.9 million in Q4 2025, and $158.3 million in Q3 2025.